Sharemaestro Newsreel

CapsoVision stock rating maintained at Speculative Buy by Benchmark

Benchmark maintained a "Speculative Buy" rating and $10.00 price target on CapsoVision Inc (NASDAQ:CV) despite recent delays in regulatory clearance for its products. The company reported increased usage of its CapsoCam Plus, with FDA clearance for its AI-assisted reading feature expected by Q3, and …

Is BioMarin Pharmaceutical (BMRN) Outperforming Other Medical Stocks This Year?

BioMarin Pharmaceutical (BMRN) is outperforming the Medical sector and its specific industry year-to-date, with a 15.3% return compared to the sector's 3%. The company holds a Zacks Rank #2 (Buy) due to improving analyst sentiment. Cardinal Health (CAH) is another medical stock showing strong …

Oppenheimer Adjusts PT on Abeona Therapeutics to $21 From $22, Maintains Outperform Rating

Oppenheimer has revised its price target for Abeona Therapeutics (ABEO) to $21 from $22, while reiterating an Outperform rating on the stock. This adjustment comes after Abeona Therapeutics' shares fell following a Q2 earnings miss. The article also provides a company profile, recent news, …

Delcath Systems updates bylaws to designate Delaware courts as exclusive forum

Delcath Systems (NASDAQ:DCTH) has amended its bylaws to designate Delaware courts as the exclusive forum for internal corporate claims and federal district courts for claims under the Securities Act of 1933. This decision, effective immediately, follows a recommendation from the Nominating and Corporate Governance …

Skye Bioscience (NASDAQ: SKYE) exits obesity trial, pursues Redx merger and $100M+ funding

Skye Bioscience is discontinuing its nimacimab obesity program and pursuing a merger with Redx Pharma to form Fibrx Therapeutics, Inc. This strategic shift addresses significant financial strains, as evidenced by a $23.3 million net loss and a substantial doubt about its ability to continue …

Skye Bioscience, Inc. 2026: Revenue $178.2K, EPS ($0.27) — 10-Q Summary

Skye Bioscience, Inc. reported its 2026 quarterly results, showing revenue of $178.2K and a net loss of ($10.79M), leading to a diluted loss per share of ($0.27), which is an improvement over the prior year. The company also announced the termination of its CBeyond …

UBS Adjusts Schrodinger PT to $19 From $13, Maintains Neutral Rating

UBS has adjusted its price target for Schrodinger, Inc. (SDGR) to $19 from $13, while maintaining a Neutral rating on the stock. This update comes after several recent news items for Schrodinger, including their Q2 2026 earnings call and revenue report, and new strategic …

Benchmark reiterates Belite Bio stock rating on FDA priority review

Benchmark reiterated a Buy rating and a $217.00 price target for Belite Bio (NASDAQ:BLTE) after the FDA granted Priority Review to the company's New Drug Application for Tinlarebant, setting a PDUFA target date of February 12, 2027. The company plans a commercial launch in …

Clover Health Is Proving Its Profit Model (NASDAQ:CLOV)

Form 8K Quince Therapeutics Inc For: 14 August By Investing.com

This article reports on the filing of a Form 8K by Quince Therapeutics Inc. on August 14. The financial document is brief and focuses solely on this specific filing for the mentioned date. It appears to be a standard notification without extensive details provided …

Zenas BioPharma's (ZBIO) Outperform Rating Reiterated at Wedbush

Wedbush reiterated its "outperform" rating on Zenas BioPharma (NASDAQ:ZBIO) with a $45 price target, indicating a potential 54.11% upside. Despite this positive analyst sentiment, the company reported a significant miss on its quarterly earnings and revenue estimates. Other analysts have also adjusted their ratings, …

Avoro, Aghazadeh report 7.06% Hemab Therapeutics (COAG) ownership stake

Avoro Capital Advisors LLC, Avoro Ventures LLC, and Behzad Aghazadeh have collectively reported a beneficial ownership stake of 7.06% in Hemab Therapeutics Holdings, Inc. (COAG). This ownership comprises 3,298,236 shares of common stock, acquired solely for investment purposes on behalf of their respective funds. …

Avoro Capital discloses 9.64% Arrowhead Pharmaceuticals (ARWR) stake including warrants

Avoro Capital Advisors LLC and its controlling person Behzad Aghazadeh have disclosed a beneficial ownership of 9.64% in Arrowhead Pharmaceuticals (ARWR). This stake includes 13,823,383 shares of Common Stock, of which 2,467,828 shares are issuable upon the exercise of warrants. The investment firm holds …

HC Wainwright Has Negative View of Talphera FY2029 Earnings

HC Wainwright has lowered its FY2029 earnings per share estimate for Talphera (NASDAQ:TLPH) to $0.12 from $0.13, while reiterating a "Buy" rating and a $3.00 price target. The firm also projected FY2030 EPS at $0.32. Talphera's stock has a "Hold" consensus rating from analysts, …

Crinetics Pharmaceuticals merger with Vertex Pharmaceuticals advances after regulatory clearances

The proposed merger between Crinetics Pharmaceuticals (NASDAQ:CRNX) and Vertex Pharmaceuticals (NASDAQ:VRTX) has progressed after securing regulatory clearances, including the expiration of the Hart-Scott-Rodino Antitrust Improvements Act waiting period and approvals in Austria, Germany, and Australia. The acquisition, valued at approximately $10 billion, is expected …

Kura Oncology FY2029 EPS Cut by Brookline Capital Markets

Equities Analysts Offer Predictions for MNPR FY2029 Earnings

Equities Analysts Offer Predictions for CADL FY2028 Earnings

HC Wainwright Has Bullish Estimate for ACRV FY2030 Earnings

Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY); Bloom Energy Corporation (NYSE: BE); Erasca, Inc. (NASDAQ: ERAS); and Insulet Corporation (NASDAQ: PODD): Grabar Law Office is Investigating Claims on Your Behalf

Grabar Law Office is investigating potential breaches of fiduciary duty by officers and directors of ARS Pharmaceuticals, Inc., Bloom Energy Corporation, Erasca, Inc., and Insulet Corporation. The investigations concern various allegations including misleading statements regarding product timelines, supply chain reliance, and manufacturing issues, which …

RIGL Maintained by HC Wainwright & Co. -- Price Target Raised to $85

HC Wainwright & Co. maintained a "Buy" rating for Rigel Pharmaceuticals (RIGL), increasing its price target from $57.00 to $85.00, reflecting confidence in the company's future growth. Despite this, Rigel Pharmaceuticals is currently priced at $42.10, which is 56.7% overvalued compared to its GF …

Canton Strategic's locking-as-a-service offering generated about $1.3M

Canton Strategic Holdings, Inc. Releases Second Quarter 2026 Financial and Operational Results

Form 8K Lantern Pharma Inc For: 14 August By Investing.com

This article reports on the filing of a Form 8K by Lantern Pharma Inc. on August 14th. It is a brief announcement indicating a regulatory filing, without providing further details about the content of the 8K. The article is from Investing.com and is dated …

Form 8K TuHURA Biosciences Inc For: 14 August By Investing.com

This article reports that TuHURA Biosciences Inc. filed a Form 8K on August 14. The filing is a standard regulatory disclosure and contains no further details within this brief report, beyond mentioning the company's stock symbol, HURA, which was up 7.39% at the time …

Capricor Therapeutics (CAPR) Stock Surges on FDA Application Amendment Plans

Outlook Therapeutics (OTLK) Q3 Earnings Miss Highlight Valuation Challenges

Is Galectin Therapeutics Inc (GALT) Overvalued After Q2 Earnings Miss? GF Score: 22/100

Capricor Therapeutics (CAPR) Stock Surges on FDA Application Ame

Stifel reiterates Buy rating on Oculis stock, $40 target

Stifel has reiterated a Buy rating and a $40 price target for Oculis Holding AG (NASDAQ:OCS), based on discussions about its lead asset, privosegtor. Despite a recent stock drop and an "overvalued" assessment by InvestingPro, analysts maintain a strong buy consensus. Oculis is shifting …

Brokers Offer Predictions for RAPP Q1 Earnings

HC Wainwright Issues Pessimistic Outlook for UTHR Earnings

Noble Financial Has Pessimistic View of UNCY Q2 Earnings

HC Wainwright Has Negative Estimate for Erasca Q3 Earnings

PDS Biotechnology shareholders approve charter amendment and director elections

PDS Biotechnology Corporation shareholders have approved an amendment to the company's certificate of incorporation, increasing the number of authorized common shares from 150 million to 300 million. They also elected two Class B directors, Kamil Ali-Jackson and Ilian Iliev, and ratified KPMG US LLP …

Research Analysts Issue Forecasts for BCRX Q4 Earnings